Bussiness3 months ago
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
Nanobiotix S.A. RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3...
